Filing Flows

Filing Flows › 8-K events › Teleflex

Teleflex: results of operations

Form 8-K filed Nov 5, 2026 · items 2.02, 7.01

FDA decisionsTeleflex Reports Third Quarter Finan cial Results and Full Year 2026 Outlook

What the filing says

Teleflex Reports Third Quarter Finan cial Results and Full Year 2026 Outlook Maintaining Pro Forma Adjusted Constant Currency Revenue Growth Guidance Range of 3.5% to 4.5%

Read the filing on SEC EDGAR →

What usually followsAcross 69,115 8-Ks reporting Item 2.02 (results of operations) in our universe, the stock's median move the next session was +0.2% (typical size ±3.6%, up 51% of the time); over the following 21 sessions, +1.2%. Every item ranked →

Teleflex at a glance

Latest quarterQ3 2026
Revenue$567.8M
Revenue Y/Y+0.1%
Operating margin18.6%
IndustrySurgical & Medical Instruments & Apparatus

Teleflex, Q3 2026: revenue $568M (+0.1% year over year), operating margin 18.6%. The chart follows the revenue to costs, profit and cash.

Teleflex: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent fda decisions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.